[1] Schwabe R F, Brenner D A. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease[J].Nat Rev Gastroenterol Hepatol, 2025, 22(7):481-499.
[2] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):151-166.
[3] Rahimi S, Derakhshani A, Alifarsangi A, et al. Immunomodulatory effects of stem cell therapy in liver fibrosis: a systematic review[J].Iran J Allergy Asthma Immunol, 2025, 24(6):718-733.
[4] Yang X, Li Q, Liu W, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment[J].Cell Mol Immunol, 2023, 20(6):583-599.
[5] Wang Z, Zhong D, Yan T, et al. Stem cells from human exfoliated deciduous teeth-derived exosomes for the treatment of acute liver injury and liver fibrosis[J].ACS Appl Mater Interfaces, 2025, 17(12):17948-17964.
[6] Fang Y, Chen L, Yuan Y, et al. Human menstrual blood-derived stem cells secreted ECM1 directly interacts with LRP1α to ameliorate hepatic fibrosis through FoxO1 and mTOR signaling pathway[J].Stem Cell Res Ther, 2025, 16(1):230.
[7] Yi Y F, Fan Z Q, Liu C, et al. Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells[J].World J Stem Cells, 2025, 17(3):103560.
[8] Gong T, Liu L, Jiang W, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases[J].Nat Rev Immunol, 2020, 20(2):95-112.
[9] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J].Mol Asp Med, 2019, 65:37-55.
[10] Wang S, Li K, Pickholz E, et al. An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis[J].Sci Transl Med, 2023, 15(677):eadd3949.
[11] Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J].Nat Rev Gastroenterol Hepatol, 2023, 20(10):633-646.
[12] Shojaie L, Iorga A, Dara L. Cell death in liver diseases: a review[J].Int J Mol Sci,2020,21(24):9682.
[13] Huang T, Zhang C, Shang Z, et al. Bone mesenchymal stem cells improve cholestatic liver fibrosis by targeting ULK1 to regulate autophagy through PI3K/AKT/mTOR pathway[J].Stem Cells Transl Med, 2024, 13:648-660.
[14] Huang T, Nie L, Diao H, et al. Bone mesenchymal stem cells attenuate hepatic stellate cell activation and liver fibrosis through REDD1/autophagy pathway [J].Stem Cells Transl Med, 2025, 14(7):szaf023.
[15] Zhou Q, Rong C, Gu T, et al. Mesenchymal stem cells improve liver fibrosis and protect hepatocytes by promoting microRNA-148a-5p-mediated inhibition of Notch signaling pathway[J].Stem Cell Res Ther, 2022, 13(1):354.
[16] Yao Y, Xia Z, Cheng F, et al. Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells[J].Stem Cell Res Ther, 2021, 12(1):294.
[17] Yao L, Hu X, Dai K, et al. Mesenchymal stromal cells: promising treatment for liver cirrhosis[J].Stem Cell Res Ther, 2022, 13(1):308.
[18] Cao Y, Ji C, Lu L. Mesenchymal stem cell therapy for liver fibrosis/cirrhosis[J]. Ann Transl Med, 2020, 8(8):562.
[19] Yi Q, Yang J, Wu Y, et al. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells[J].Front Immunol, 2023, 14:1204524.
[20] Feng X, Feng B, Zhou J, et al. Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells[J].Hepatology, 2025, 81(4):1211-1227.
[21] Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J].Hepatology, 2019, 70(5):1714-1731.
[22] Liu J, Gao J, Liang Z, et al. Mesenchymal stem cells and their microenvironment[J].Stem Cell Res Ther, 2022, 13(1):429.
[23] Chen Q H, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro[J].Stem Cell Res Ther, 2020, 11(1):91.
[24] Psaraki A, Ntari L, Karakostas C, et al. Extracellular vesicles derived from mesenchymal stem/stromal cells: the regenerative impact in liver diseases[J].Hepatology, 2022, 75(6):1590-1603.
[25] Tian S, Zhou X, Zheng L, et al. Engineered mesenchymal stem cell-derived small extracellular vesicles mitigate liver fibrosis by delivering USP10 to reprogram macrophage phenotype[J].Biomater Res, 2025, 29:0244.
[26] Mincheva G, Moreno-Manzano V, Felipo V, et al. Extracellular vesicles from mesenchymal stem cells improve liver injury in rats with mild liver damage. Underlying mechanisms and role of TGFβ[J].Life Sci, 2025, 364:123429.
[27] Yadav S, Maity P, Kapat K. The opportunities and challenges of mesenchymal stem cells-derived exosomes in theranostics and regenerative medicine [J].Cells, 2024, 13(23):1956.
[28] Gan L, Zheng L, Yao L, et al. Exosomes from adipose-derived mesenchymal stem cells improve liver fibrosis by regulating the miR-20a-5p/TGFBR2 axis to affect the p38 MAPK/NF-κB pathway[J].Cytokine, 2023, 172:156386.
[29] Rong X, Liu J, Yao X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J].Stem Cell Res Ther, 2019, 10(1):98.
[30] Tan Y, Huang Y, Mei R, et al. HucMSC-derived exosomes delivered BECN1 induces ferroptosis of hepatic stellate cells via regulating the xCT/GPX4 axis[J].Cell Death Dis, 2022, 13(4):319.
[31] Wang Z, Yuan M, Yao L, et al. Exosomal miR-499a-5p from human umbilical cord mesenchymal stem cells attenuates liver fibrosis via targeting ETS1/GPX4-mediated ferroptosis in hepatic stellate cells[J].J Nanobiotechnology, 2025, 23(1):222.
[32] Tian S, Zhou X, Zhang M, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages[J].Stem Cell Res Ther, 2022, 13(1):330.
[33] Tao H, Liu Q, Zeng A, et al. Unlocking the potential of mesenchymal stem cells in liver fibrosis: insights into the impact of autophagy and aging[J].Int Immunopharmacol, 2023, 121:110497.
[34] Zhang J, Lu T, Xiao J, et al. MSC-derived extracellular vesicles as nanotherapeutics for promoting aged liver regeneration[J].J Control Release, 2023, 356:402-415.
[35] Wang H Y, Li C, Liu W H, et al. Autophagy inhibition via Becn1 downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis[J].J Cell Physiol, 2020, 235(3):2722-2737.
[36] Wang Y, Piao C, Liu T, et al. Effects of the exosomes of adipose-derived mesenchymal stem cells on apoptosis and pyroptosis of injured liver in miniature pigs[J].Biomed Pharmacother, 2023, 169:115873.
[37] Harrell C R, Volarevic V. Apoptosis: a friend or foe in mesenchymal stem cell-based immunosuppression[J].Adv Protein Chem Struct Biol, 2021, 126:39-62.
[38] Zhang Y, Zhangdi H, Nie X, et al. Exosomes derived from BMMSCs mitigate the hepatic fibrosis via anti-pyroptosis pathway in a cirrhosis model[J].Cells, 2022, 11(24):4004.
[39] Didamoony M A, Soubh A A, Ahmed L A. Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes[J].Drug Deliv Transl Res,2025, 15(8):2608-2623.
[40] Zhang J, Qiu X, Lei Y, et al. Engineered EVs from LncEEF1G-overexpressing MSCs promote fibrotic liver regeneration by upregulating HGF release from hepatic stellate cells[J].Exp Mol Med, 2025, 57(3):584-600.
[41] Kim J Y, Park H, Park S Y, et al. Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis[J].Clin Mol Hepatol, 2025, 31(3):823-840.
[42] Zhu D, Sun Z, Wei J, et al. BMP7-Loaded human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorate liver fibrosis by targeting sctivated hepatic stellate cells[J].Int J Nanomedicine, 2024, 19:3475-3495.
[43] Park H W, Lee D H, Kim S, et al. Amphiphilic lipid-peptide engineered placenta-derived mesenchymal stem cells for liver fibrosis treatment[J].Asian J Pharm Sci, 2025, 20(4):101061.
[44] Mendes B B, Conniot J, Avital A, et al. Nanodelivery of nucleic acids[J].Nat Rev Methods Primers, 2022, 2:24.
[45] Fan L, Wei A, Gao Z, et al. Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy[J].Biomed Pharmacother, 2023, 161:114451.
[46] Tian Y, Sun D, Liu N, et al. Biomimetic mesenchymal stem cell membrane-coated nanoparticle delivery of MKP5 inhibits hepatic fibrosis through the IRE/XBP1 pathway[J].J Nanobiotechnology, 2024, 22(1):741.
[47] Xiong Z, Chen P, Wang Z, et al. Human umbilical cord-derived mesenchymal stem cells attenuate liver fibrosis by inhibiting hepatocyte ferroptosis through mitochondrial transfer[J].Free Radic Biol Med, 2025, 231:163-177.
[48] Liu W, Liu Y, Zhang L, et al. Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis[J].Nat Commun, 2025, 16(1):4517.
[49] Chen S, Wu Z, Zhang J, et al. Research and application of medicines for treating liver fibrosis: current status and prospects[J].Front Pharmacol, 2025, 16:1582258. |
